Merck Says The Program Violates Its First And Fifth Amendment Rights; Says Medicare To Start Negotiating Prices For Some Drugs In 2026 Under The Inflation Reduction Act
Portfolio Pulse from Benzinga Newsdesk
Merck has claimed that the Inflation Reduction Act, which allows Medicare to negotiate drug prices starting in 2026, violates its First and Fifth Amendment rights, according to the Wall Street Journal.
June 06, 2023 | 1:59 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Merck claims the Inflation Reduction Act, allowing Medicare to negotiate drug prices in 2026, violates its constitutional rights, potentially impacting its future revenues.
Merck's claim that the Inflation Reduction Act violates its constitutional rights could lead to legal battles and potential changes in the legislation. If Medicare is allowed to negotiate drug prices, it may result in lower revenues for Merck in the future, negatively impacting its stock price in the short term.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100